Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Eholie SP, Moh R, Benalycherif A, Gabillard D, Ello F, Messou E, Zoungrana J, Diallo I, Diallo M, Bado G, Cisse M, Maiga AI, Anzian A, Toni TD, Congo-Ouedraogo M, Toure-Kane C, Seydi M, Minta DK, Sawadogo A, Sangaré L, Drabo J, Karcher S, Le Carrou J, de Monteynard LA, Peytavin G, Gabassi A, Girard PM, Chaix ML, Anglaret X, Landman R; Thilao ANRS 12269 Study Group. Eholie SP, et al. Among authors: benalycherif a. Lancet HIV. 2019 Nov;6(11):e750-e759. doi: 10.1016/S2352-3018(19)30228-0. Epub 2019 Oct 7. Lancet HIV. 2019. PMID: 31601544
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.
Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, Bonnet B, Yeni P, Bentata M, Michelet C, Benalycherif A, Brun Vezinet F, Miller MD, Flandre P; TONUS (IMEA 021) Study Group. Landman R, et al. Among authors: benalycherif a. HIV Clin Trials. 2005 Nov-Dec;6(6):291-301. doi: 10.1310/9DQP-R7JA-75ED-RBCP. HIV Clin Trials. 2005. PMID: 16452063 Clinical Trial.
Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients.
Landman R, Poupard M, Diallo M, Ngom Gueye NF, Diakhate N, Ndiaye B, Toure Kane C, Trylesinski A, Diop H, Mboup S, Koita Fall MB, Delaporte E, Benalycherif A, Girard PM, Sow PS. Landman R, et al. Among authors: benalycherif a. J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):379-84. doi: 10.1177/1545109709344352. Epub 2009 Sep 15. J Int Assoc Physicians AIDS Care (Chic). 2009. PMID: 19755618 Clinical Trial.
CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.
Lewden C, Gabillard D, Minga A, Ekouévi DK, Avit D, Konate I, Amani-Bossé C, Messou E, Coffie P, Ouedraogo A, Laurent C, Anglaret X; ANRS 12222 MorbidityMortality Study Group. Lewden C, et al. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):213-9. doi: 10.1097/QAI.0b013e31823b837e. J Acquir Immune Defic Syndr. 2012. PMID: 22027874 Free PMC article.
AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.
Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group. Anglaret X, et al. Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4. Clin Infect Dis. 2012. PMID: 22173233 Free PMC article.
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group. Gabillard D, et al. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821. J Acquir Immune Defic Syndr. 2013. PMID: 23274931 Free PMC article.
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM; DAYANA Study Group. Landman R, et al. Among authors: benalycherif a. Antivir Ther. 2014;19(1):51-9. doi: 10.3851/IMP2675. Epub 2013 Aug 23. Antivir Ther. 2014. PMID: 23970206 Clinical Trial.
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G; DAYANA Study Group. Lê MP, et al. Among authors: benalycherif a. J Antimicrob Chemother. 2015 May;70(5):1517-21. doi: 10.1093/jac/dku532. Epub 2015 Jan 11. J Antimicrob Chemother. 2015. PMID: 25583749 Clinical Trial.
29 results